<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>RDM Cardiovascular Medicine</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/0DAFD6C5-C3C2-4386-A502-EF77E8EC4A3C"><gtr:id>0DAFD6C5-C3C2-4386-A502-EF77E8EC4A3C</gtr:id><gtr:firstName>Joshua</gtr:firstName><gtr:otherNames>Tian Yun</gtr:otherNames><gtr:surname>Chai</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FK00266X%2F1"><gtr:id>48E988CA-6D01-4E46-A1DC-96B77A29B4C9</gtr:id><gtr:title>Integrated functional characterisation in acute vascular syndromes: multimodal MRI / PET-CT imaging combined with leukocyte expression profiling</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>MR/K00266X/1</gtr:grantReference><gtr:abstractText>Circulatory disease, such as heart attacks and strokes, remain the most common cause of death in the UK, contributing to almost one-third of all deaths registered in 2010. Each year, over 180,000 people die from circulatory disease in the UK alone, with 82,000 deaths from coronary heart disease and a further 49,000 from stroke. This costs the UK in excess of &amp;pound;30 billion each year due to healthcare associated costs and loss of workforce productivity. Despite this very substantial burden of disease, tools for identifying patients at high risk of acute vascular events remain extremely limited. As a consequence, a large proportion of events are unheralded. Even in patients with established disease, inability to distinguish patients at high and low risk means that optimal treatments cannot be targeted rationally and cost-effectively.

It is well recognised that the final common events of arterial blockage in heart attack and strokes are often the results of arterial thrombosis (blood clots forming within arteries). Arterial thrombosis is commonly triggered by ruptured fatty deposits within the arterial wall known as atherosclerotic plaques. Despite considerable efforts in the past decade, no single imaging modality has succeeded in accurately identifying these high-risk, &amp;quot;vulnerable&amp;quot; plaques. The need for better plaque and patient characterisation has now become even more urgent and pressing, with a new generation of cardiovascular drugs near the clinical horizon, which directly target plaque behaviour and biology with no anticipated effect on plaque size and are therefore not detectable by conventional imaging techniques.
 
The purpose of our proposed research is to use sophisticated, high-end laboratory techniques to first define the characteristics of plaque constituent cells from explanted human tissue following acute stroke. We can then relate this molecular &amp;quot;signature&amp;quot; to plaque imaging characteristic using state-of-the-art techniques with MRI, as well as PET nuclar imaging, which can detect plaques' biological activity. By combining imaging data and cellular analysis, we aim to evaluate the cellular events that drive plaque activity, and to generate a unique characterisation of patients at risk.

We will develop a multimodal vascular imaging protocol with MRI/PET-CT in Oxford that can be validated at a cellular or molecular level within the plaque constituent cells. With our new research-dedicated Oxford Acute Vascular Imaging Centre (AVIC), and the strong tie between the University and the NHS, Oxford is strategically poised to lead research into the early phase of acute vascular syndromes. Through this innovative project, we hope to generate tools that will aid (1) diagnosis and risk stratification, (2) monitoring response to treatment (3) evaluation of new drugs and interventions - all of which reflect pressing current clinical unmet need.</gtr:abstractText><gtr:technicalSummary>Hypotheses: (i) atherosclerotic plaques with an increased 18FDG-PET signal reflect macrophages deep within the plaque core that display a &amp;quot;hypoxic&amp;quot; gene profile; (ii) superficial macrophages in the shoulder regions of plaque (responsible for cap disruption and acute events) express an &amp;quot;inflammatory&amp;quot; gene profile and are not associated with 18FDG-PET signal; (iii) peripheral blood monocytes' gene expression profile will reflect the activation status of these superficial cells and may be useful as a systemic biomarker.
Primary objective: To define the gene expression characteristics (signature) of macrophages and /or macrophage-derived foam cells from explanted human carotid plaque following acute stroke and endarterectomy, and to relate this molecular &amp;quot;signature&amp;quot; to plaque characteristic using MRI/PET-CT.
Secondary objective: To study the differential contribution of hypoxia versus inflammation in overall plaque vulnerability in patients with recent stroke, and to help further define the functional significance of 18FDG signal used in vascular inflammation PET imaging.
Tertiary objective: To evaluate potential blood soluble/cellular biomarkers of plaque instability.
Methodology: A case-control observational study of patients undergoing carotid endarterectomy. Up to 25 patients with recent TIA/stroke and with &amp;gt;60% ipsilateral carotid stenosis on screening ultrasound will undergo study imaging protocol (3T MRI &amp;amp; PET-CT). Control will be asymptomatic individuals scheduled to undergo carotid endarterectomy, matched to similar severity of carotid disease. Following endarterectomy, a small part of each plaque will be processed for conventional light microscopy for micro-structure, and the larger part will be subjected to immunohistochemistry and laser capture micro-dissection (LCM) to extract location-specific plaque macrophages/foam cells. Following LCM, mRNA will be extracted from isolated cells and under go linear RNA amplification before microarray gene analysis.</gtr:technicalSummary><gtr:potentialImpactText>The socio-economical impacts of our proposed research are accentuated by scale of worldwide health burden due to the complications of atherosclerosis. Cardiovascular disease, such as heart attacks and strokes, remain the most common cause of death in the UK, contributing to almost one-third of all deaths registered in 2010. Each year, over 180,000 people die from circulatory disease in the UK alone, with 82,000 deaths from coronary heart disease and a further 49,000 from stroke. This costs the UK in excess of &amp;pound;30 billion each year due to healthcare associated costs and loss of workforce productivity. Our research output aims at providing better characterisation of patients at risk and will allow us to tailor existing and new interventions more rationally and cost-effectively to patients in different risk strata. In addition to helping the NHS and Government decision-makers to target the increasingly limited resources more effectively, our research output will reflect and resonate the MRC's initiative to place UK at the forefront of development into personalised medicine.

One particular area that will see a significant economical benefit is in the development of future pharmaceuticals. The failure of CETP inhibitor torcetrapib in the ILLUMINATE trial demonstrated there is still scope for new drugs to fail catastrophically at an advanced stage of development, costing patient lives and huge commercial expense. Risk of similar failure may be avoided by the development and application of multimodal functional imaging techniques of the sort we propose. These may provide early insights into the biological effects of interventions by providing imaging &amp;quot;biomarkers&amp;quot; that can be readily related to both pathogenesis and clinical outcome. Applied in Phase II, imaging could guide 'go' versus 'no-go' decision-making in the efficient evaluation of potentially promising compounds. This is of critical importance as new generation of anti-atherosclerotic drugs such as inhibitor of I-1; CCR2; and p38 MAP kinase, are already near the clinical horizon (Phase II-III) and current imaging tools remain inadequate for such purpose.

Furthermore, our currently proposed multimodal imaging protocol (MRI + 18FDG-PET) will set the platform for evaluation of future innovative functional imaging agents. Currently in Phase II trial in Oxford (Principal Investigator Professor Fergus Gleeson, our project collaborator) is another PET tracer (18F-RGD, fluciclatide) developed by GE Healthcare to image angiogenesis in solid tumours. Angiogenesis is thought to be related to plaque hypoxia, which is an important determinant of plaque instability. It is foreseeable that future multimodal imaging can potentially incorporate other biological or functional tracer like 18F-RGD using our research output as benchmark comparison.

Finally, although this proposal does not specifically aim at generating commercially-exploitable technology, we will remain vigilant for any potential opportunity to generate intellectual property - e.g. part of our project involves the analysis of gene expression profile (&amp;quot;signature&amp;quot;) in peripheral blood cells, which may become commercially exploitable as a systemic &amp;quot;biomarker&amp;quot; for high risk atherosclerosis in the future.</gtr:potentialImpactText><gtr:fund><gtr:end>2015-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>212410</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>7B5E8FD0-EEE7-45D2-98DE-5D992FEDD89C</gtr:id><gtr:title>Quantification of Lipid-Rich Core in Carotid Atherosclerosis Using Magnetic Resonance T&amp;nbsp;Mapping: Relation to Clinical Presentation.</gtr:title><gtr:parentPublicationTitle>JACC. Cardiovascular imaging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/50b51e635d4ac85d8bcf9c805bca6a1a"><gtr:id>50b51e635d4ac85d8bcf9c805bca6a1a</gtr:id><gtr:otherNames>Chai JT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1876-7591</gtr:issn><gtr:outcomeId>58979632d74bd6.41432316</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D80A5411-32A1-4CDB-8DD0-22108BC092CB</gtr:id><gtr:title>GPR109A and vascular inflammation.</gtr:title><gtr:parentPublicationTitle>Current atherosclerosis reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/50b51e635d4ac85d8bcf9c805bca6a1a"><gtr:id>50b51e635d4ac85d8bcf9c805bca6a1a</gtr:id><gtr:otherNames>Chai JT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1523-3804</gtr:issn><gtr:outcomeId>pm_22860_20_23526298</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A6C425BF-0007-4F66-BC5C-18B24B5AE582</gtr:id><gtr:title>Inflammatory processes in cardiovascular disease: a route to targeted therapies.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/150002ef498516feb0d0018eee1de8e0"><gtr:id>150002ef498516feb0d0018eee1de8e0</gtr:id><gtr:otherNames>Ruparelia N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1759-5002</gtr:issn><gtr:outcomeId>58979632a05881.54082179</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>80B53BD9-51BB-4555-AF54-3169E16F3859</gtr:id><gtr:title>Characterisation of carotid plaques by in-vivo quantitative T2 mapping: histological validation and lipid quantification</gtr:title><gtr:parentPublicationTitle>European Heart Journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ec6869af6a68b6f675e514c617b6f9f3"><gtr:id>ec6869af6a68b6f675e514c617b6f9f3</gtr:id><gtr:otherNames>Joshua T Chai</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>545a68b9dce909.91007274</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF15F0F4-28AC-44D1-A243-A1F617C7A23E</gtr:id><gtr:title>Cardiometabolic interventions - focus on transcriptional regulators.</gtr:title><gtr:parentPublicationTitle>The European journal of cardiovascular medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/50b51e635d4ac85d8bcf9c805bca6a1a"><gtr:id>50b51e635d4ac85d8bcf9c805bca6a1a</gtr:id><gtr:otherNames>Chai JT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2042-4884</gtr:issn><gtr:outcomeId>pm_22860_20_24040490</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5F763C8F-7ABB-481D-A5F4-A721108F14B8</gtr:id><gtr:title>Acute myocardial infarction activates distinct inflammation and proliferation pathways in circulating monocytes, prior to recruitment, and identified through conserved transcriptional responses in mice and humans.</gtr:title><gtr:parentPublicationTitle>European heart journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/150002ef498516feb0d0018eee1de8e0"><gtr:id>150002ef498516feb0d0018eee1de8e0</gtr:id><gtr:otherNames>Ruparelia N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0195-668X</gtr:issn><gtr:outcomeId>56ddb8d40fab43.95493562</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6924097C-182D-4D1C-B73F-4B03313FD004</gtr:id><gtr:title>Nicotinic acid receptor GPR109A is down-regulated in human macrophage-derived foam cells.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/50b51e635d4ac85d8bcf9c805bca6a1a"><gtr:id>50b51e635d4ac85d8bcf9c805bca6a1a</gtr:id><gtr:otherNames>Chai JT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_22860_20_23658787</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FD42C188-A851-4E71-A24F-B6922250498B</gtr:id><gtr:title>In-vivo quantitative T2 mapping of carotid arteries in atherosclerotic patients: segmentation and T2 measurement of plaque components.</gtr:title><gtr:parentPublicationTitle>Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ebf5d73606106aa7f0a17ad9ab53181f"><gtr:id>ebf5d73606106aa7f0a17ad9ab53181f</gtr:id><gtr:otherNames>Biasiolli L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1097-6647</gtr:issn><gtr:outcomeId>pm_22860_20_23953780</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C74D494D-BADC-4ED1-A20F-BB8061685904</gtr:id><gtr:title>Black-blood multicontrast imaging of carotid arteries with DANTE-prepared 2D and 3D MR imaging.</gtr:title><gtr:parentPublicationTitle>Radiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0cd97b4a1e149c4f95df16a9cd3b6324"><gtr:id>0cd97b4a1e149c4f95df16a9cd3b6324</gtr:id><gtr:otherNames>Li L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0033-8419</gtr:issn><gtr:outcomeId>545a681011ef11.45084383</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>70D0A144-2593-4317-9DCE-780DD77719FD</gtr:id><gtr:title>Plaque imaging to refine indications for emerging lipid-lowering drugs.</gtr:title><gtr:parentPublicationTitle>European heart journal. Cardiovascular pharmacotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9c68d010de111a24168bf75e4ce4a088"><gtr:id>9c68d010de111a24168bf75e4ce4a088</gtr:id><gtr:otherNames>Alkhalil M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5897963277dd18.47216483</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>867AB87A-8BDA-410A-A995-33AA6CB6341F</gtr:id><gtr:title>Multimeric micro particles of iron oxide (mMPIO) for dual modality molecular imaging with CT and MRI</gtr:title><gtr:parentPublicationTitle>European Heart Journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e2046197eb00fba193a7ffc7d8e3cb92"><gtr:id>e2046197eb00fba193a7ffc7d8e3cb92</gtr:id><gtr:otherNames>Alaa A A Aljabali</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>545a6944ab0d20.54882785</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>61306F06-3381-40FD-9EB1-6BA39CC48BE9</gtr:id><gtr:title>Vascular and Endovascular Consensus Update</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ec6869af6a68b6f675e514c617b6f9f3"><gtr:id>ec6869af6a68b6f675e514c617b6f9f3</gtr:id><gtr:otherNames>Joshua T Chai</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:isbn>978-0-9570419-2-9</gtr:isbn><gtr:outcomeId>545a6743364817.12076152</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/K00266X/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>D4FDB752-4E9C-491F-9C63-B7D7F6F95417</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Cardiovascular</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>A77DAE3A-499B-4F46-971D-6C82F51F9C2E</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Stroke</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>3BEA012A-C817-4067-8BE1-05331EBB5152</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.2  Evaluation of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>